Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Operationally Seamless Phase 2/3 Randomized, Open-label, Active-Controlled Study Evaluating the Safety and Efficacy of an Injectable Regimen of GS-3242 in Combination With Lenacapavir Versus Biktarvy (Bictegravir/Emtricitabine/Tenofovir Alafenamide) in Treatment-Naive People With HIV-1

NCT07708727 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT07708727
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07708727 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Operationally Seamless Phase 2/3 Randomized, Open-label, Active-Controlled Study Evaluating the Safety and Efficacy of an Injectable Regimen of GS-3242 in Combination With Lenacapavir Versus Biktarvy (Bictegravir/Emtricitabine/Tenofovir Alafenamide) in Treatment-Naive People With HIV-1
Lead sponsor
Gilead Sciences
Phase
Phase 2/3
Overall status
Recruiting
Start date
July 29, 2026
Completion date
April 30, 2033
Enrollment
700 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

hiv-1-infection